JP2005504721A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005504721A5 JP2005504721A5 JP2002569084A JP2002569084A JP2005504721A5 JP 2005504721 A5 JP2005504721 A5 JP 2005504721A5 JP 2002569084 A JP2002569084 A JP 2002569084A JP 2002569084 A JP2002569084 A JP 2002569084A JP 2005504721 A5 JP2005504721 A5 JP 2005504721A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- formulated
- activator
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000203 mixture Substances 0.000 claims 161
- 150000001875 compounds Chemical class 0.000 claims 56
- 239000012190 activator Substances 0.000 claims 24
- 239000000674 adrenergic antagonist Substances 0.000 claims 21
- 239000004036 potassium channel stimulating agent Substances 0.000 claims 13
- 230000001713 cholinergic effect Effects 0.000 claims 12
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 claims 11
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 claims 11
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 10
- 102000009346 Adenosine receptors Human genes 0.000 claims 10
- 108050000203 Adenosine receptors Proteins 0.000 claims 10
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 claims 10
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 claims 10
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 10
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims 10
- 230000001800 adrenalinergic effect Effects 0.000 claims 10
- 239000000808 adrenergic beta-agonist Substances 0.000 claims 10
- 229940125714 antidiarrheal agent Drugs 0.000 claims 10
- 239000003793 antidiarrheal agent Substances 0.000 claims 10
- 229940049706 benzodiazepine Drugs 0.000 claims 10
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 10
- 239000003112 inhibitor Substances 0.000 claims 10
- 210000005036 nerve Anatomy 0.000 claims 10
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims 10
- 229940127291 Calcium channel antagonist Drugs 0.000 claims 9
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 claims 9
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 claims 9
- 239000000480 calcium channel blocker Substances 0.000 claims 9
- 229940075993 receptor modulator Drugs 0.000 claims 9
- 239000000050 smooth muscle relaxant Substances 0.000 claims 9
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 claims 8
- 102000030621 adenylate cyclase Human genes 0.000 claims 8
- 108060000200 adenylate cyclase Proteins 0.000 claims 8
- 230000001076 estrogenic effect Effects 0.000 claims 8
- 239000002516 radical scavenger Substances 0.000 claims 8
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 7
- 239000006071 cream Substances 0.000 claims 7
- 229940126513 cyclase activator Drugs 0.000 claims 7
- 239000006260 foam Substances 0.000 claims 7
- 239000000499 gel Substances 0.000 claims 7
- 238000003780 insertion Methods 0.000 claims 7
- 230000037431 insertion Effects 0.000 claims 7
- 239000006210 lotion Substances 0.000 claims 7
- 239000003921 oil Substances 0.000 claims 7
- 239000002674 ointment Substances 0.000 claims 7
- 239000006072 paste Substances 0.000 claims 7
- 239000000843 powder Substances 0.000 claims 7
- 239000000243 solution Substances 0.000 claims 7
- 239000007921 spray Substances 0.000 claims 7
- 239000000829 suppository Substances 0.000 claims 7
- 239000000725 suspension Substances 0.000 claims 7
- 230000002459 sustained effect Effects 0.000 claims 7
- 229940044953 vaginal ring Drugs 0.000 claims 7
- 239000006213 vaginal ring Substances 0.000 claims 7
- 239000006216 vaginal suppository Substances 0.000 claims 7
- 229940120293 vaginal suppository Drugs 0.000 claims 7
- 238000000034 method Methods 0.000 claims 5
- 239000002840 nitric oxide donor Substances 0.000 claims 5
- -1 NO donors Substances 0.000 claims 4
- 229940122361 Bisphosphonate Drugs 0.000 claims 3
- 150000004663 bisphosphonates Chemical class 0.000 claims 3
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims 3
- 125000001572 5'-adenylyl group Chemical group C=12N=C([H])N=C(N([H])[H])C=1N=C([H])N2[C@@]1([H])[C@@](O[H])([H])[C@@](O[H])([H])[C@](C(OP(=O)(O[H])[*])([H])[H])([H])O1 0.000 claims 2
- 101710095468 Cyclase Proteins 0.000 claims 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 claims 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 claims 2
- 229960004373 acetylcholine Drugs 0.000 claims 2
- 239000000262 estrogen Substances 0.000 claims 2
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims 2
- 238000011200 topical administration Methods 0.000 claims 2
- 208000004483 Dyspareunia Diseases 0.000 claims 1
- 102000030168 Endothelin A Receptor Human genes 0.000 claims 1
- 108010090549 Endothelin A Receptor Proteins 0.000 claims 1
- 229940118365 Endothelin receptor antagonist Drugs 0.000 claims 1
- 208000021663 Female sexual arousal disease Diseases 0.000 claims 1
- 206010020565 Hyperaemia Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 102000016924 KATP Channels Human genes 0.000 claims 1
- 108010053914 KATP Channels Proteins 0.000 claims 1
- 241001313288 Labia Species 0.000 claims 1
- 102000016469 Large-Conductance Calcium-Activated Potassium Channels Human genes 0.000 claims 1
- 108010092555 Large-Conductance Calcium-Activated Potassium Channels Proteins 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 102000004257 Potassium Channel Human genes 0.000 claims 1
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000002308 endothelin receptor antagonist Substances 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 108020001213 potassium channel Proteins 0.000 claims 1
- 230000004648 relaxation of smooth muscle Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 230000002889 sympathetic effect Effects 0.000 claims 1
- 229960003604 testosterone Drugs 0.000 claims 1
- 208000000143 urethritis Diseases 0.000 claims 1
- 230000028973 vesicle-mediated transport Effects 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27390101P | 2001-03-06 | 2001-03-06 | |
| US33490301P | 2001-10-24 | 2001-10-24 | |
| PCT/US2002/007026 WO2002069906A2 (en) | 2001-03-06 | 2002-03-06 | Compounds and methods for the treatment of urogenital disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005504721A JP2005504721A (ja) | 2005-02-17 |
| JP2005504721A5 true JP2005504721A5 (enExample) | 2005-12-22 |
Family
ID=26956497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002569084A Withdrawn JP2005504721A (ja) | 2001-03-06 | 2002-03-06 | 尿生殖障害の処置のための化合物および方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6987129B2 (enExample) |
| EP (1) | EP1383502A4 (enExample) |
| JP (1) | JP2005504721A (enExample) |
| KR (2) | KR20040052489A (enExample) |
| CA (1) | CA2440141A1 (enExample) |
| IL (1) | IL157734A0 (enExample) |
| MX (1) | MXPA03007960A (enExample) |
| WO (1) | WO2002069906A2 (enExample) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8512718B2 (en) | 2000-07-03 | 2013-08-20 | Foamix Ltd. | Pharmaceutical composition for topical application |
| US20030162769A1 (en) * | 2002-02-26 | 2003-08-28 | Easterling W. Jerry | Composition and method for treating vulvodynia |
| US20050176782A1 (en) * | 2002-02-26 | 2005-08-11 | Easterling W. J. | Medicament and method for treating vulodynia |
| GB0219660D0 (en) | 2002-08-23 | 2002-10-02 | Astrazeneca Ab | Therapeutic use |
| IL152486A0 (en) | 2002-10-25 | 2003-05-29 | Meir Eini | Alcohol-free cosmetic and pharmaceutical foam carrier |
| US20060140984A1 (en) | 2002-10-25 | 2006-06-29 | Foamix Ltd. | Cosmetic and pharmaceutical foam |
| US9211259B2 (en) | 2002-11-29 | 2015-12-15 | Foamix Pharmaceuticals Ltd. | Antibiotic kit and composition and uses thereof |
| US9265725B2 (en) | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US8486376B2 (en) | 2002-10-25 | 2013-07-16 | Foamix Ltd. | Moisturizing foam containing lanolin |
| US8900554B2 (en) | 2002-10-25 | 2014-12-02 | Foamix Pharmaceuticals Ltd. | Foamable composition and uses thereof |
| US20080138296A1 (en) | 2002-10-25 | 2008-06-12 | Foamix Ltd. | Foam prepared from nanoemulsions and uses |
| US9668972B2 (en) | 2002-10-25 | 2017-06-06 | Foamix Pharmaceuticals Ltd. | Nonsteroidal immunomodulating kit and composition and uses thereof |
| US7704518B2 (en) | 2003-08-04 | 2010-04-27 | Foamix, Ltd. | Foamable vehicle and pharmaceutical compositions thereof |
| US7820145B2 (en) | 2003-08-04 | 2010-10-26 | Foamix Ltd. | Oleaginous pharmaceutical and cosmetic foam |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US8119150B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Non-flammable insecticide composition and uses thereof |
| US10117812B2 (en) | 2002-10-25 | 2018-11-06 | Foamix Pharmaceuticals Ltd. | Foamable composition combining a polar solvent and a hydrophobic carrier |
| US8119109B2 (en) | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| CA2510292A1 (en) * | 2002-12-20 | 2004-07-15 | Dynogen Pharmaceuticals, Inc. | Methods of treating non-painful bladder disorders using .alpha.2.delta. subunit calcium channel modulators |
| US6863825B2 (en) | 2003-01-29 | 2005-03-08 | Union Oil Company Of California | Process for removing arsenic from aqueous streams |
| US20100187178A1 (en) * | 2003-01-29 | 2010-07-29 | Molycorp Minerals, Llc | Process for removing and sequestering contaminants from aqueous streams |
| KR100742001B1 (ko) * | 2003-03-21 | 2007-07-23 | 다이노젠 파마세우티컬스, 인코포레이티드 | 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법 |
| US7575739B2 (en) | 2003-04-28 | 2009-08-18 | Foamix Ltd. | Foamable iodine composition |
| US8486374B2 (en) | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
| US8795693B2 (en) | 2003-08-04 | 2014-08-05 | Foamix Ltd. | Compositions with modulating agents |
| ES2258694T3 (es) * | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
| US8784869B2 (en) | 2003-11-11 | 2014-07-22 | Mattern Pharma Ag | Controlled release delivery system for nasal applications and methods of treatment |
| PL1685849T3 (pl) * | 2003-11-20 | 2012-07-31 | Astellas Pharma Inc | Inhibitory PDE 4 do leczenia śródmiąższowego zapalenia pęcherza moczowego |
| US20050181057A1 (en) * | 2004-02-13 | 2005-08-18 | Rosenberg Paul K. | Vaginal lubricant |
| GB0403744D0 (en) | 2004-02-20 | 2004-03-24 | Astrazeneca Ab | Chemical process |
| JP2007526316A (ja) * | 2004-03-01 | 2007-09-13 | ルーメン セラピューティックス リミテッド ライアビリティ カンパニー | 疾患を処置するための組成物および方法 |
| JP4808613B2 (ja) * | 2004-03-24 | 2011-11-02 | キッセイ薬品工業株式会社 | 頻尿または尿失禁の予防または治療用医薬 |
| WO2005092321A1 (ja) * | 2004-03-24 | 2005-10-06 | Kissei Pharmaceutical Co., Ltd. | 頻尿または尿失禁の予防または治療用医薬組成物 |
| CN101027061B (zh) | 2004-05-11 | 2014-03-12 | 情感智能有限责任公司 | 药物制剂及其在治疗女性性功能障碍中的应用 |
| CN106038572A (zh) * | 2004-10-20 | 2016-10-26 | 恩多研究公司 | 性甾体前体单独或与选择性雌激素受体调节剂联合用于预防和治疗绝经后女性的性功能障碍 |
| US20060140820A1 (en) | 2004-12-28 | 2006-06-29 | Udo Mattern | Use of a container of an inorganic additive containing plastic material |
| US20070004745A1 (en) * | 2005-03-25 | 2007-01-04 | Schering-Plough Corporation | Methods of treating benign prostatic hyperplasia or lower urinary tract symptoms by using PDE 5 inhibitors |
| EP1881821B1 (en) * | 2005-05-20 | 2016-11-09 | Omeros Corporation | Compositions comprising ketoprofen and calcium channel antagonist for use in urological procedures |
| EP1790343A1 (en) * | 2005-11-11 | 2007-05-30 | Emotional Brain B.V. | Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction |
| US20070264130A1 (en) * | 2006-01-27 | 2007-11-15 | Phluid, Inc. | Infusion Pumps and Methods for Use |
| WO2007120485A2 (en) * | 2006-03-30 | 2007-10-25 | Cinergen, Llc | Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor |
| PT2359826E (pt) * | 2006-07-05 | 2014-01-20 | Takeda Gmbh | Combinação de um inibidor da hmg-coa redutase rosuvastatina e um inibidor da fosfodiesterase 4, tais como roflumilaste, óxido de n-roflumilaste, para o tratamento de doenças pulmonares inflamatórias |
| DK2068825T3 (da) | 2006-10-04 | 2011-05-16 | M & P Patent Ag | Kontrolleret frisætningstilførselssystem til nasal påføring af neurotransmittere |
| EP1925307A1 (en) | 2006-11-03 | 2008-05-28 | Emotional Brain B.V. | Use of 3-alpha-androstanediol in the treatment of sexual dysfunction |
| US20080260655A1 (en) | 2006-11-14 | 2008-10-23 | Dov Tamarkin | Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses |
| WO2008073961A2 (en) * | 2006-12-12 | 2008-06-19 | Emory University | Compounds and methods for modulating the silencing of a polynucleotide of interest |
| US8066874B2 (en) | 2006-12-28 | 2011-11-29 | Molycorp Minerals, Llc | Apparatus for treating a flow of an aqueous solution containing arsenic |
| US20110171195A1 (en) * | 2007-06-15 | 2011-07-14 | Duke University | Methods and compositions for treating urinary tract infections using agents that mimic or elevate cyclic amp |
| US8636982B2 (en) | 2007-08-07 | 2014-01-28 | Foamix Ltd. | Wax foamable vehicle and pharmaceutical compositions thereof |
| CA2698683A1 (en) * | 2007-09-07 | 2009-03-12 | Epigenesis Pharmaceuticals, Llc | Dheas inhalation compositions |
| EP2042179A1 (en) * | 2007-09-26 | 2009-04-01 | sanofi-aventis | Novel therapeutic uses of adrenergic alpha-1 receptor antagonists |
| US20090107919A1 (en) * | 2007-10-31 | 2009-04-30 | Chevron U.S.A. Inc. | Apparatus and process for treating an aqueous solution containing chemical contaminants |
| US20090107925A1 (en) * | 2007-10-31 | 2009-04-30 | Chevron U.S.A. Inc. | Apparatus and process for treating an aqueous solution containing biological contaminants |
| US8252087B2 (en) | 2007-10-31 | 2012-08-28 | Molycorp Minerals, Llc | Process and apparatus for treating a gas containing a contaminant |
| US8349764B2 (en) | 2007-10-31 | 2013-01-08 | Molycorp Minerals, Llc | Composition for treating a fluid |
| WO2009069006A2 (en) | 2007-11-30 | 2009-06-04 | Foamix Ltd. | Foam containing benzoyl peroxide |
| WO2009072007A2 (en) | 2007-12-07 | 2009-06-11 | Foamix Ltd. | Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof |
| WO2010041141A2 (en) | 2008-10-07 | 2010-04-15 | Foamix Ltd. | Oil-based foamable carriers and formulations |
| AU2009205314A1 (en) | 2008-01-14 | 2009-07-23 | Foamix Ltd. | Poloxamer foamable pharmaceutical compositions with active agents and/or therapeutic cells and uses |
| US8986253B2 (en) * | 2008-01-25 | 2015-03-24 | Tandem Diabetes Care, Inc. | Two chamber pumps and related methods |
| US8987245B2 (en) | 2008-04-02 | 2015-03-24 | Jonathan R. Brestoff Parker | Composition and method for affecting obesity and related conditions |
| US8598150B1 (en) | 2008-04-02 | 2013-12-03 | Jonathan R. Brestoff | Composition and method for affecting obesity and related conditions |
| EP2276525A4 (en) * | 2008-05-19 | 2012-04-04 | Tandem Diabetes Care Inc | REMOVABLE PUMP CONTAINER AND RELATED METHOD |
| US8408421B2 (en) | 2008-09-16 | 2013-04-02 | Tandem Diabetes Care, Inc. | Flow regulating stopcocks and related methods |
| EP2334234A4 (en) * | 2008-09-19 | 2013-03-20 | Tandem Diabetes Care Inc | DEVICE FOR MEASURING THE CONCENTRATION OF A SOLVED SUBSTANCE AND CORRESPONDING METHOD |
| US20100087402A1 (en) * | 2008-09-29 | 2010-04-08 | Vivus, Inc. | Methods and compositions for the treatment of estrogen-dependent hyperproliferative uterine disorders |
| TW201038510A (en) * | 2009-03-16 | 2010-11-01 | Molycorp Minerals Llc | Porous and durable ceramic filter monolith coated with a rare earth for removing contaminates from water |
| MX2011010666A (es) * | 2009-04-09 | 2012-01-27 | Molycorp Minerals Llc | Uso de una tierra rara para la remocion de antimonio y bismuto. |
| US20120087872A1 (en) | 2009-04-28 | 2012-04-12 | Foamix Ltd. | Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof |
| US8946209B2 (en) * | 2009-04-28 | 2015-02-03 | Optmed, Inc. | Compositions and methods for treating and preventing urolithiasis and conditions associated therewith |
| JP2012525402A (ja) * | 2009-04-28 | 2012-10-22 | オプトメッド インコーポレイテッド | 過活動膀胱およびそれに関連する状態を、治療するおよび予防するための、組成物および方法 |
| CA2769677A1 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses |
| WO2011013009A2 (en) | 2009-07-29 | 2011-02-03 | Foamix Ltd. | Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses |
| US8758323B2 (en) * | 2009-07-30 | 2014-06-24 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| US8563261B2 (en) * | 2009-09-28 | 2013-10-22 | The Trustees Of The University Of Pennsylvania | Method of diagnosing and treating interstitial cystitis |
| US9849142B2 (en) | 2009-10-02 | 2017-12-26 | Foamix Pharmaceuticals Ltd. | Methods for accelerated return of skin integrity and for the treatment of impetigo |
| AU2010302350B2 (en) | 2009-10-02 | 2015-06-18 | Journey Medical Corporation | Surfactant-free water-free foamable compositions, breakable foams and gels and their uses |
| EP2499679A4 (en) * | 2009-11-09 | 2014-01-01 | Molycorp Minerals Llc | REMOVAL OF STAINING FROM RARE EARTH |
| IT1397000B1 (it) * | 2009-11-12 | 2012-12-20 | Antropoli | Uso di un preparato basato sulla nifedipina per il trattamento del vaginismo |
| US12661407B2 (en) | 2010-04-08 | 2026-06-23 | Journey Medical Corporation | Compositions, gels and foams with rheology modulators and uses thereof |
| WO2012094426A2 (en) * | 2011-01-04 | 2012-07-12 | Schwartz Alan N | Gel-based seals and fixation devices and associated systems and methods |
| US9233863B2 (en) | 2011-04-13 | 2016-01-12 | Molycorp Minerals, Llc | Rare earth removal of hydrated and hydroxyl species |
| US20130040923A1 (en) | 2011-05-13 | 2013-02-14 | Trimel Pharmaceuticals Corporation | Intranasal lower dosage strength testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US20130045958A1 (en) | 2011-05-13 | 2013-02-21 | Trimel Pharmaceuticals Corporation | Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder |
| US9757388B2 (en) | 2011-05-13 | 2017-09-12 | Acerus Pharmaceuticals Srl | Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels |
| US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| EP2782584B1 (en) | 2011-11-23 | 2021-06-09 | TherapeuticsMD, Inc. | Natural combination hormone replacement formulations and therapies |
| US9180242B2 (en) | 2012-05-17 | 2015-11-10 | Tandem Diabetes Care, Inc. | Methods and devices for multiple fluid transfer |
| US9555186B2 (en) | 2012-06-05 | 2017-01-31 | Tandem Diabetes Care, Inc. | Infusion pump system with disposable cartridge having pressure venting and pressure feedback |
| US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
| MX378538B (es) * | 2012-08-09 | 2025-03-10 | Can Fite Biopharma Ltd | Ligandos del receptor de adenosina a3 para su uso en el tratamiento de una disfuncion sexual. |
| US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
| US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| US9173998B2 (en) | 2013-03-14 | 2015-11-03 | Tandem Diabetes Care, Inc. | System and method for detecting occlusions in an infusion pump |
| US11744838B2 (en) | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| WO2015051336A1 (en) | 2013-10-03 | 2015-04-09 | David Wise | Compositions and methods for treating pelvic pain and other conditions |
| MX370462B (es) | 2014-03-07 | 2019-12-13 | Secure Natural Resources Llc | Oxido de cerio (iv) con propiedades de remocion de arsenico excepcionales. |
| AR100562A1 (es) | 2014-05-22 | 2016-10-12 | Therapeuticsmd Inc | Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal |
| MX2020012139A (es) | 2016-09-08 | 2021-01-29 | Vyne Pharmaceuticals Inc | Composiciones y metodos para tratar rosacea y acne. |
| WO2018227172A1 (en) * | 2017-06-08 | 2018-12-13 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
| CA3085013A1 (en) | 2017-12-13 | 2019-06-20 | Onquality Pharmaceuticals China Ltd. | A method for preventing or treating egfr-inhibition associated diseases |
| IL258017B (en) | 2018-03-11 | 2019-10-31 | Aquafit Intimate Ltd | Intravaginal device and uses thereof |
| CN113975264A (zh) | 2018-04-16 | 2022-01-28 | 上海岸阔医药科技有限公司 | 预防或治疗肿瘤疗法副作用的方法 |
| TWI710371B (zh) * | 2018-05-10 | 2020-11-21 | 國立臺灣師範大學 | 鎳錯合物用於製備緩解膀胱發炎的藥物之用途 |
| US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1163561A (en) | 1979-11-06 | 1984-03-13 | Cyril Boroda | Preparation containing nitroglycerine and optionally other medicaments and preparation thereof |
| JPS56133381A (en) | 1980-03-25 | 1981-10-19 | Nippon Kayaku Co Ltd | Pressure-sensitive adhesive tape or sheet containing nitroglycerin |
| IL61721A (en) | 1980-12-16 | 1984-03-30 | Blank Izhak | Nitroglycerin preparations |
| US4559222A (en) | 1983-05-04 | 1985-12-17 | Alza Corporation | Matrix composition for transdermal therapeutic system |
| US4681584A (en) | 1985-05-03 | 1987-07-21 | Alza Corporation | Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes |
| US4655766A (en) | 1985-08-01 | 1987-04-07 | Alza Corporation | Fluid imbibing pump with self-regulating skin patch |
| CA1272922A (en) | 1986-06-03 | 1990-08-21 | Peter William Berry | Drug delivery device, its preparation and use |
| US5071656A (en) | 1987-03-05 | 1991-12-10 | Alza Corporation | Delayed onset transdermal delivery device |
| US5300291A (en) | 1988-03-04 | 1994-04-05 | Noven Pharmaceuticals, Inc. | Method and device for the release of drugs to the skin |
| US5698589A (en) | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
| US5595970A (en) | 1993-07-16 | 1997-01-21 | Schering Aktiengesellschaft | Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors |
| US5565466A (en) | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| US5731339A (en) | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| US6323211B1 (en) * | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
| US6294517B1 (en) | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
| US6331543B1 (en) * | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
| US5958926A (en) | 1996-11-01 | 1999-09-28 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
| DE19726255C2 (de) | 1997-06-20 | 2000-03-16 | Mucos Pharma Gmbh & Co | Beeinflussung von Cytokinen durch proteolytische Enzyme und Rutosid |
| CA2294480C (en) | 1997-06-23 | 2008-05-20 | Queen's University At Kingston | Microdose therapy of female sexual dysfunction by no, co, and their donors |
| AU740758B2 (en) * | 1997-10-28 | 2001-11-15 | Vivus, Inc. | Treatment of female sexual dysfunction |
| US5877216A (en) | 1997-10-28 | 1999-03-02 | Vivus, Incorporated | Treatment of female sexual dysfunction |
| EP1089736A2 (en) | 1998-06-22 | 2001-04-11 | Queen's University At Kingston | Method and compositions for the treatment or amelioration of female sexual dysfunction |
| US6143300A (en) * | 1998-08-11 | 2000-11-07 | Robin Ann Stevenot | Fem-Ease, a supplement for the symptoms of cystitis, urinary tract infections and premenstrual syndrome |
| AU3490300A (en) * | 1999-03-12 | 2000-10-04 | Nitromed, Inc. | Dopamine agonists in combination with nitric oxide donors, compositions and methods of use |
| US6417207B1 (en) * | 1999-05-12 | 2002-07-09 | Nitromed, Inc. | Nitrosated and nitrosylated potassium channel activators, compositions and methods of use |
| KR20010076961A (ko) | 2000-01-29 | 2001-08-17 | 김제종 | 성기능장애 예방 및 치료용 약제 |
-
2002
- 2002-03-06 WO PCT/US2002/007026 patent/WO2002069906A2/en not_active Ceased
- 2002-03-06 MX MXPA03007960A patent/MXPA03007960A/es not_active Application Discontinuation
- 2002-03-06 KR KR10-2003-7011650A patent/KR20040052489A/ko not_active Ceased
- 2002-03-06 JP JP2002569084A patent/JP2005504721A/ja not_active Withdrawn
- 2002-03-06 EP EP02723359A patent/EP1383502A4/en not_active Withdrawn
- 2002-03-06 CA CA002440141A patent/CA2440141A1/en not_active Abandoned
- 2002-03-06 IL IL15773402A patent/IL157734A0/xx unknown
- 2002-03-06 US US10/094,409 patent/US6987129B2/en not_active Expired - Fee Related
- 2002-03-06 KR KR1020107005297A patent/KR20100036390A/ko not_active Ceased
-
2005
- 2005-09-26 US US11/236,096 patent/US20060030622A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Davis et al. | Mirtazapine for pruritus | |
| JP2002542147A5 (enExample) | ||
| AU660650B2 (en) | Use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis B | |
| CA2267893C (en) | Method and potentiated composition for treating migraine | |
| US20090275586A1 (en) | Heterocyclic inhibitors of pde4 | |
| DE60018274D1 (de) | Substituierte 4-oxo-chinolin-3-carboxamide als gaba gehirnrezeptorliganden | |
| WO2006081327A2 (en) | Small molecules that reduce fungal growth | |
| BR0010348A (pt) | Uso de antagonistas seletivos de receptor <244>~ 1b~-adrenérgico para aperfeiçoamento de disfunção sexual | |
| MA31311B1 (fr) | Dérivés d'indazole substitués par oxadiazole, destinés à être utilisés comme agonistes de la sphingosine 1-phosphate (s1p) | |
| MA27703A1 (fr) | Derives de diazepino-indole servant d'inhibiteurs de kinases | |
| MA28064A1 (fr) | Dérivés de pyrrolo [3,4-c] pyrazole actifs comme inhibiteurs de kinases | |
| US20020151543A1 (en) | Compositions and methods employing R (-) fluoxetine and other active ingredients | |
| BR0108965A (pt) | Derivados de 3-(diarilmetileno)-8-azabiciclo[3,2,1]octano | |
| PE20010924A1 (es) | Compuestos inhibidores de fosfodiesterasa utiles para el tratamiento de la disfuncion sexual femenina | |
| EP1027011A4 (en) | ADMINISTRATION OF 5-HT RECEPTOR AGONISTS AND ANTAGONISTS INCLUDING ACTIVE SUBSTANCES FOR THE TREATMENT OF EARLY SEED EATING | |
| MA31867B1 (fr) | Agonistes nouveaux des recepteurs de glucocorticoides | |
| US5021410A (en) | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure | |
| WO2005000807A3 (en) | Benzodiazepine cgrp receptor antagonists | |
| MA26964A1 (fr) | Association d'agonistes de gaba et d'inhibiteurs de sorbitol-deshydrogenase. | |
| JP2009539800A (ja) | Ｃｇｒｐ拮抗薬による胃腸障害の治療 | |
| SG165316A1 (en) | Combination of a long-acting hypnotic agent and a short-acting hypnotic agent and therapeutic use of same | |
| NO20024364L (no) | Anvendelse av pyrido [3,2-E]-pyrazinoner som inhibitorer av fosfodiesterase 5 for behandling av erektil dysfunksjon | |
| ES2196898T3 (es) | Antagonistas de receptores de crf y metodos relacionados. | |
| Bassiouni et al. | Evaluation of some prostaglandins modulators on rat corpus cavernosum in-vitro: Is relaxation negatively affected by COX-inhibitors? | |
| WO2003094853A3 (en) | Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |